Tomorrow could be fun ---Preclinical study shows Ocera's lead product candidate halts progression of liver fibrosis in NAFLD model; shares up 39% after hours
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.